Stellar Biotechnologies Issues Corporate Update

PORT HUENEME, CA--(Marketwired - Oct 23, 2015) -  Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today issued a corporate update from its President, Chief Executive Officer, and Chairman Frank Oakes. 

Stellar Biotechnologies is working at the crossroads of two important global trends -- the exploration of immunotherapy as a potential game-changing treatment of serious diseases, and an integrated approach to the conservation and sustainable development of the oceans' essential resources.

As a biotechnology company and leading KLH manufacturer, we are focused on the commercial expansion of Stellar KLH™ products in immunotherapy and the clinical advancement of KLH-based immunotherapies against cancer, immune disorders, Alzheimer's disease, and inflammatory diseases. 

As a public company, we are committed to transforming these commercial and clinical objectives into value for our shareholders.

On behalf of the hard-working team at Stellar Biotechnologies, I am proud to recap the Company's recent milestones and the advantageous position we believe we are building on the forefront of immunotherapy development.

Collaboration and Supply Agreements:

Through our collaboration and supply agreements, Stellar KLH™ is now a key ingredient in clinical-stage immunotherapies targeting metastatic breast cancer, ovarian cancer, Alzheimer's disease, lupus, and Crohn's disease. 

We believe our corporate relationships reinforce the role of KLH as a carrier molecule in immunotherapy treatments, and serve as examples of Stellar's KLH business driving clinical and commercial milestones. Recent events related to our partners' programs include:

Update on Collaboration with Amaran Biotechnology

Stellar and Amaran Biotechnology, Inc. have completed all primary objectives of our collaboration to develop methods for the manufacture of OBI-822 immunotherapy, the flagship product of OBI Pharma, Inc., a publicly-traded Taiwan biotech company. Stellar KLH™ is the immune-stimulating carrier molecule in OBI-822 which is currently in a late-stage multinational clinical trial for the treatment of metastatic breast cancer.